Amphastar Competitors
| AMPH Stock | USD 28.24 0.32 1.15% |
Amphastar vs Beta Bionics Correlation
Good diversification
The correlation between Amphastar P and BBNX is -0.02 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Amphastar P and BBNX in the same portfolio, assuming nothing else is changed.
Moving together with Amphastar Stock
| 0.64 | GSK | GlaxoSmithKline PLC ADR Earnings Call Tomorrow | PairCorr |
Moving against Amphastar Stock
| 0.53 | CNSP | CNS Pharmaceuticals | PairCorr |
| 0.49 | PIFMY | Indofood Sukses Makmur | PairCorr |
| 0.46 | PTAIF | PT Astra International | PairCorr |
| 0.33 | ALTS | ALT5 Sigma | PairCorr |
| 0.33 | SNOA | Sonoma Pharmaceuticals | PairCorr |
Amphastar Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Amphastar and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Amphastar and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Amphastar P does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Amphastar Stock performing well and Amphastar Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Amphastar's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| DVAX | 1.73 | 0.64 | 0.44 | 0.67 | 0.66 | 2.76 | 39.08 | |||
| COLL | 1.79 | 0.44 | 0.18 | 1.28 | 1.76 | 4.61 | 20.06 | |||
| PCRX | 2.14 | (0.07) | 0.00 | (0.03) | 0.00 | 4.50 | 14.20 | |||
| CVAC | 1.22 | (0.22) | 0.00 | (0.57) | 0.00 | 3.33 | 18.10 | |||
| EMBC | 1.96 | (0.36) | 0.00 | 1.10 | 0.00 | 3.87 | 16.06 | |||
| HROW | 2.71 | 0.13 | 0.04 | 0.23 | 2.93 | 7.65 | 21.82 | |||
| SNDX | 2.72 | 0.66 | 0.31 | 0.51 | 1.87 | 8.70 | 18.37 | |||
| INBX | 3.01 | 0.34 | 0.08 | (28.81) | 3.63 | 6.04 | 23.28 | |||
| AHCO | 1.96 | 0.12 | 0.04 | 0.34 | 2.19 | 4.17 | 24.44 | |||
| BBNX | 3.53 | (0.69) | 0.00 | (0.78) | 0.00 | 6.89 | 47.68 |
Cross Equities Net Income Analysis
Compare Amphastar P and related stocks such as Dynavax Technologies, Collegium Pharmaceutical, and Pacira BioSciences Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DVAX | (26.7 M) | (48.6 M) | (69.9 M) | (66.7 M) | (90.7 M) | (106.8 M) | (112.4 M) | (95.2 M) | (158.9 M) | (152.6 M) | (75.2 M) | 76.7 M | 293.2 M | (6.4 M) | 27.3 M | 31.4 M | 33 M |
| COLL | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (17.9 M) | (27.3 M) | (94.2 M) | (74.9 M) | (39.1 M) | (22.7 M) | 26.8 M | 71.5 M | (25 M) | 48.2 M | 69.2 M | 79.6 M | 83.5 M |
| PCRX | (41.9 M) | (43.3 M) | (52.3 M) | (63.9 M) | (13.7 M) | 1.9 M | (37.9 M) | (42.6 M) | (471 K) | (11 M) | 145.5 M | 42 M | 15.9 M | 42 M | (99.6 M) | (114.5 M) | (108.8 M) |
| CVAC | (71.2 M) | (71.2 M) | (71.2 M) | (71.2 M) | (71.2 M) | (71.2 M) | (71.2 M) | (71.2 M) | (71.2 M) | (99.9 M) | (129.1 M) | (411.7 M) | (249 M) | (260.2 M) | 162.2 M | 186.5 M | 195.8 M |
| EMBC | 432 M | 432 M | 432 M | 432 M | 432 M | 432 M | 432 M | 432 M | 432 M | 427.6 M | 414.8 M | 223.6 M | 70.4 M | 78.3 M | 95.4 M | 85.9 M | 81.6 M |
| HROW | (46.2 K) | (954 K) | (5.4 M) | (7.6 M) | (10.1 M) | (15.9 M) | (19.1 M) | (12 M) | 14.6 M | 168 K | (3.4 M) | (18 M) | (14.1 M) | (24.4 M) | (17.5 M) | (15.7 M) | (14.9 M) |
| SNDX | (13.1 M) | (13.1 M) | (10 M) | (14.2 M) | (19.8 M) | (24.1 M) | (44.5 M) | (60.8 M) | (74 M) | (56 M) | (73.1 M) | 24.9 M | (143.7 M) | (209.4 M) | (318.8 M) | (286.9 M) | (272.5 M) |
| INBX | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (19.4 M) | (31.2 M) | (51.4 M) | (75.6 M) | (81.8 M) | (145.2 M) | (241.4 M) | 1.7 B | 1.9 B | 2 B |
| AHCO | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (690) | 2.1 M | (21.3 M) | (161.6 M) | 156.2 M | 69.3 M | (678.9 M) | 90.4 M | 81.4 M | 85.4 M |
| BBNX | (64.8 M) | (64.8 M) | (64.8 M) | (64.8 M) | (64.8 M) | (64.8 M) | (64.8 M) | (64.8 M) | (64.8 M) | (64.8 M) | (64.8 M) | (64.8 M) | (64.8 M) | (44.1 M) | (54.8 M) | (63 M) | (66.1 M) |
Amphastar P and related stocks such as Dynavax Technologies, Collegium Pharmaceutical, and Pacira BioSciences Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Amphastar P financial statement analysis. It represents the amount of money remaining after all of Amphastar P operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Amphastar Competitive Analysis
The better you understand Amphastar competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Amphastar's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Amphastar's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Amphastar Competition Performance Charts
Five steps to successful analysis of Amphastar Competition
Amphastar's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Amphastar P in relation to its competition. Amphastar's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Amphastar in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Amphastar's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Amphastar P, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Amphastar position
In addition to having Amphastar in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Large Value Funds Thematic Idea Now
Large Value Funds
Funds or Etfs that invest in the undervalued stocks of large-sized companies. The Large Value Funds theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Large Value Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Amphastar Correlation with its peers. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is there potential for Pharmaceuticals market expansion? Will Amphastar introduce new products? Factors like these will boost the valuation of Amphastar. If investors know Amphastar will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Amphastar listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.53) | Earnings Share 2.26 | Revenue Per Share | Quarterly Revenue Growth 0.003 | Return On Assets |
The market value of Amphastar P is measured differently than its book value, which is the value of Amphastar that is recorded on the company's balance sheet. Investors also form their own opinion of Amphastar's value that differs from its market value or its book value, called intrinsic value, which is Amphastar's true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Amphastar's market value can be influenced by many factors that don't directly affect Amphastar's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Amphastar's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Amphastar represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Amphastar's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.